Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus

International Journal of Clinical Pharmacology Research

Volumn 22, Issue 3-4, 2002, Pages 89-99

  Castano G ^a   Menendez R ^b   Más, Rosa ^b   Amor, A ^b   Fernandez J L ^b   Gonzalez R L ^b   Lezcay, M ^a   Alvarez, E ^b  

^a Medical Surgical Research Center   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKADIENE; ANTIDIABETIC AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; COPPER ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MUSCLE RELAXANT AGENT; POLICOSANOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PARALLEL DESIGN; PATIENT SELECTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TABLET; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

AGED; ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPID PEROXIDATION; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0038715438     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Frick M.H., Elo O., Happa K., et al. Helsinki Heart Study: Primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N. Eng. J. Med., 317, 1237, 1987.
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results I. Reduction in the incidence of coronary heart disease. JAMA, 251, 351, 1984.
3. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA, 251, 365, 1984.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383, 1994.
5. Sacks F.M., Pfeffer M.A., Moyé L.A., et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001, 1996.
6. Tonkin A., Aylward P., Colqhoun D., et al. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Eng. J. Med., 339, 1349, 1998.
7. Shepherd S., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 333, 1301, 1995.
8. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2486, 2001.
9. Pyorala K., De Backer G., Graham I., et al. on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Published simultaneously in Eur. Heart J., 15, 300, 1994 and Atherosclerosis, 110, 121, 1994.
10. Pyorala K., De Backer G., Graham I., et al. on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Published simultaneously in Eur. Heart J., 15, 300, 1994 and Atherosclerosis, 110, 121, 1994.
11. Wetterhall S.F., Olson D.R., DeStefano F., et al. Trends in diabetes and diabetic complications. Diabetes Care, 15, 960, 1992.
12. Sasaki A., Uehara M., Horiuchi N., et al. A 15 year follow-up study of patients with non-insulin dependent diabetes mellitus (NIDDM) in Osaka, Japan. Long-term prognosis and causes of death. Diabetes Res. Clin. Pract., 34, 47, 1996.
13. Rosengren A., Welin L., Tsipogianni L., et al. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: A general population study. Br. Med. J., 299, 1127, 1989.
14. Laakso M., Ronnemaa T., Lehto S., et al. Does NIDDM increase the risk for coronary heart disease similarly on both low- and high-risk populations? Diabetologia, 38, 487, 1995.
15. Laakso M. Epidemiology of diabetic dyslipidemia. Diabetes Rev., 3, 408, 1995.
16. Buccala R., Makita Z., Vega G., Grundy S.M., et al. Modification of low density lipoprotein by advanced glycation end-products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA, 91, 9441, 1994.
17. Hunt J.V., Dean R.T., Wolff S.P. Oxidative glycation and free radical production: A causal mechanism of diabetic complication. Free Rad. Res. Commun., 12-13, 115, 1991.
18. Jennings P.E., Jones A.F., Florkouski C.M., et al. Increased diene conjugates in diabetic subjects with microangiopathy. Diabetic Med., 4, 452, 1987.
19. Abbot C.A., Mackness M.I., Kumar S., et al. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoprotein. Arterioscler. Thromb. Vasc. Biol., 15, 1812, 1995.
20. Ikeda Y., Suchiro T., Inoue M. Serum paraoxonase activity and its relation to diabetic complications in patients with non-insulin dependent diabetes mellitus. Metab. Clin. Exp., 47, 598, 1998.
21. Mackness B., Durrington P.N., Abuashia B., et al. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci., 98, 335, 2000.
22. Henwood J.M., Heel R.C. Lovastatin: A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs, 36, 429, 1988.
23. Mitchel Y.B. The long-term tolerability profile of lovastatin and simvastatin. Atherosclerosis, 97, 33, 1992.
24. Walker J.F. Worldwide experiences with simvasatin/lovastatin. Eur. Heart. J. 13 (Suppl. B), S21, 1992.
25. Aviram M., Dankner G., Cogan U., et al. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. Metabolism, 41, 229, 1992.
26. Chen L., Haught W.H., Yang B., et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as a common mechanism of antiatherogenic effects of vitamin E, lovastatin and amlopidine. J. Am. Coll. Cardiol., 30, 569, 1997.
27. Menéndez R., Fernández I., del Rio A., et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol. Res., 27, 199, 1994.
28. Menéndez R., Arruzazabala M.L., Más R., et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Brit. J. Nutr., 77, 923, 1997.
29. Pons P., Rodríguez M., Robaina C., et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int. J. Clin. Pharmacol. Res., XIV, 27, 1994.
30. Canetti M., Morera M., Illnait J., et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int. J. Clin. Pharmacol. Res., XV, 159, 1995.
31. Castaño G., Canetti M., Morera M., et al. Efficacy and tolerability of policosanol in elderly patients with type II hiperlipoproteinemia: A 12-month study. Curr. Ther. Res., 56, 819, 1995.
32. Zardoya R., Tula L., Castaño G., et al. Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function. Curr. Ther. Res., 57, 568, 1996.
33. Castaño G., Más R., Fernández J.C., et al. Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol. Endocrinol., 14, 187, 2000.
34. Más R., Castaño G., Illnait J., et al. Effect of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin. Pharmacol. Ther., 65, 439, 1998.
35. Castaño G., Más R., Arruzazabala M.L., et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int. J. Clin Pharm. Res., XIX, 105, 1999.
36. Fernández J.C., Más R., Castaño G., et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women. Clin. Invest., 21, 103, 2001.
37. Mirkin A., Mas R., Martinto M., et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int. J. Clin. Pharmacol. Res., XXI, 31, 2001.
38. Mas R., Castaño G., Fernández L., et al. Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin. Drug Invest., 21, 485, 2001.
39. Torres O., Agramonte A.J., Illnait J., et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care, 18, 393, 1995.
40. Crespo N., Alvarez R., Más R., et al. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia. Curr. Ther. Res., 58, 44, 1997.
41. Crespo N., Illnait J., Más R., et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int. J. Clin. Pharm. Res., XIX (4), 117, 1999.
42. Fernández L., Más R., Illnait J., Fernández J.C. Policosanol: Results of a postmarketing surveillance control on 27 879 cases. Curr. Ther. Res., 59, 717, 1998.
43. Más R., Rivas P., Izquierdo J.E., et al. Pharmacoepidemiologic study of policosanol. Curr. Ther. Res., 60, 458, 1999.
44. Menéndez R., Más R., Amor A.M., et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Brit. J. Clin. Pharmacol., 50, 255, 2000.
45. Menéndez R., Más R., Amor A.M., et al. Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: A ramdomized double-bind pilot study. Curr. Ther. Res., 61, 609, 2000.
46. Friedewald W.T., Levy R.I., Friederickson S.D. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without of the preparative ultracentrifuge. Clin. Chem., 18, 499, 1972.
47. Schectman G., Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am. J. Med., 100, 197, 1996.
48. Seigler L., Wu W.T. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstat and magnesium chloride. Clin. Chem., 27, 838, 1981.
49. Kleinveld H.A., Hark-Lemmers H.L.M., Stalenhoef A.F.H., et al. Improved measurements of low-density lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein. Clin. Chem., 38, 2066, 1992.
50. Esterbauer H., Striegl H., Puhl H., et al. Continuos monitoring of in vitro oxidation of human low density lipoprotein. Free Rad. Res. Commun., 6, 67, 1989.
51. Markwell M.A., Hass S.M., Bieber L.L., et al. A modification of the Lowry procedure to simply protein determination in membrane and lipoprotein samples. Anal. Biochem., 87, 206, 1987.
52. Okahua H., Ohishiwnad K., Yagi K. Assay of lipid peroxides in animal tissue by TBA. Anal. Biochem., 95, 351, 1979.
53. Garg A., Grundy S.M. Lovastatin for lowering cholesterol levels in non-insulin dependent diabetes mellitus. N. Engl. J. Med., 318, 81, 1988.
54. Golberg R., La Belle P., Zuokis R., Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent-diabetes mellitus. Am. J. Cardiol., 66, 16, 1990.
55. Bradford R.H., Shear C.S., Chremos A.N. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch. Intern. Med., 151, 43, 1991.
56. Palomäki A., Malminiemi K., Malminiemi O., et al. Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation. Arterioscler. Thromb. Vasc. Biol., 19, 1541, 1999.
57. Palomäki A., Malminiemi K., Metsa-Keleta T. Enhanced oxidizability of uboquinol and alpha-tocopherol during lovastatin treatment. FEBS Lett., 410, 254, 1997.
58. Maxwell S.R.J., Thomason H., Sandler D., et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest., 27, 484, 1997.
59. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Rad. Biol. Med., 9, 515, 1990.